Skip to main content

Limoneira Company(LMNR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

Globe Newswire - Fri Nov 12, 2021

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors

Study evaluates IK-175 in urothelial carcinoma patients including AHR positive enriched subpopulation  

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

watchlist
25 stocks most added to Watchlists